IFNβ-1a
Showing 1 - 25 of >10,000
Learn About Interferon-beta Exposure of Pregnant Women During
Not yet recruiting
- Multiple Sclerosis (MS)
- Avonex (IFNβ-1-a, Biogen Netherlands B.V)
- +5 more
-
Multiple Locations, Finland
- +1 more
Sep 19, 2023
COVID-19 Virus Infection Trial in Milano (Interferon-ß-1a, Standard of Care (SOC))
Terminated
- COVID-19 Virus Infection
- Interferon-ß-1a
- Standard of Care (SOC)
-
Milano, ItalyIRCCS Ospedale San Raffaele
Apr 28, 2021
Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma Trial in Rochester (VSV-IFNß-NIS, Pembrolizumab)
Recruiting
- Solid Tumor
- +2 more
- VSV-IFNβ-NIS
- Pembrolizumab
-
Rochester, MinnesotaMayo Clinic
Sep 26, 2022
Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG
Recruiting
- Breast Neoplasms
- +10 more
- Standard Therapy
- +32 more
-
Birmingham, Alabama
- +35 more
Nov 17, 2022
Melanoma, Non Small Cell Lung Cancer Trial in United States (VV1, Cemiplimab, Ipilumumab)
Recruiting
- Melanoma
- Non Small Cell Lung Cancer
- VV1
- +2 more
-
Phoenix, Arizona
- +22 more
Apr 21, 2022
Healthy Subjects Trial in Christchurch (EC5026 oral tablet, Placebo oral tablet)
Not yet recruiting
- Healthy Subjects
- EC5026 oral tablet
- Placebo oral tablet
-
Christchurch, New ZealandNew Zealand Clinical Research
Oct 17, 2023
Multiple Sclerosis Trial in Cairo (Blood sample collection)
Recruiting
- Multiple Sclerosis
- Blood sample collection
-
Cairo, EgyptNasser Institute for Research and Treatment
Feb 21, 2023
Ulcerative Colitis Trial in Melbourne (LIV001, Placebo)
Not yet recruiting
- Ulcerative Colitis
- LIV001
- Placebo
-
Melbourne, Victoria, AustraliaNucleus Network Pty Ltd
Jul 26, 2023
Malignant Solid Tumor Trial (GEN1042, Pembrolizumab, Cisplatin)
Not yet recruiting
- Malignant Solid Tumor
- GEN1042
- +4 more
- (no location specified)
Sep 21, 2023
Breast Cancer Trial (CBD Oral, Control)
Not yet recruiting
- Breast Cancer
- CBD Oral
- Control
- (no location specified)
Nov 18, 2023
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial
Not yet recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +5 more
- Interferon Beta-1A
- +10 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2023
Chronic Hepatitis B Trial in Hamburg (HEPLISAV B; TherVacB, TherVacB)
Not yet recruiting
- Chronic Hepatitis B
- HEPLISAV B; TherVacB
- TherVacB
-
Hamburg, GermanyCTC North
Feb 3, 2023
Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed/Refractory Large B-cell Lymphoma
- KITE-197
- +2 more
- (no location specified)
Oct 6, 2023
Brain Tumor Trial in Houston (tepotinib, tepotinib plus osimertinib)
Not yet recruiting
- Brain Tumor
- tepotinib
- tepotinib plus osimertinib
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Hemophilia A, Hemophilia B, Blood Coagulation Disorders Trial in Seoul (TU7710, Normal saline)
Recruiting
- Hemophilia A
- +2 more
- TU7710
- Normal saline
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 8, 2023
Multiple Sclerosis Trial in Shreveport (Interferon beta 1a, oral doxycycline)
Completed
- Multiple Sclerosis
- Interferon beta 1a, oral doxycycline
-
Shreveport, LouisianaLSU Health Sciences Center Shreveport
Oct 11, 2022
Lung Cancer Trial in Cambridge, Wythenshawe (OWL-EVO1)
Recruiting
- Lung Cancer
- OWL-EVO1
-
Cambridge, Cambridgeshire, United Kingdom
- +1 more
Aug 19, 2022
Advanced or Metastatic Solid Tumors Trial (PMC-309 monotherapy, PMC-309 Dose Escalation in Combination with Pembrolizumab,
Not yet recruiting
- Advanced or Metastatic Solid Tumors
- PMC-309 monotherapy
- +2 more
- (no location specified)
Jul 19, 2023
